The field of companion animal oncology has reached its highest level of growth among all veterinary medical disciplines in 2026. The growth of this industry has become evident through its impact on clinics and pharmaceutical development and supply chain operations throughout the nation. Nowadays many owners treat their pets like their own offspring. In cases of pets like cats and dogs who fall victims to cancer, owners decide on treatment rather than elephant care.
In 2025, the global veterinary oncology market reached a value of $1.74 billion. Experts predict it will grow to $3.10 billion by 2030 showing a 12.1% compound annual growth rate . This segment represents one of the most rapidly expanding areas currently found in veterinary medicine .
What’s Fueling This Demand for Cancer Care?
Cancer is a common challenge in veterinary clinics. The Veterinary Cancer Society estimates it is behind 47% of deaths in dogs older than ten years and 32% of cat deaths. Approximately 25 percent of dogs and 20 percent of cats develop abnormal growths which continue throughout their lifetime. The United States currently has an enormous pet population which includes 89.7 million dogs and 59.8 million cats according to AVMA data from 2024.
Important statistics:
- Over 6 million dogs get diagnosed with cancer each year in the U.S. (National Cancer Institute, 2025)
- Lymphoma makes up about one-fourth of all new cancer cases in dogs.
- In 2024, dogs accounted for 86.09% of the veterinary oncology market share in North America. This segment is expected to grow at a 12.56% annual rate until 2030.
- The cat segment is growing the fastest, with a predicted growth rate of 12.38% through 2030.
- In 2025, North America is estimated to lead the global market with 53.9% of revenue (Grand View Research).
It’s not diagnosis rates that have shifted—what pet owners choose to do afterward has changed too. A 2025 AAHA report shows that seven out of ten pet owners see their pets as family and aim to provide them with top-notch care.
Pet Insurance Transformed the Cost Equation
The high price of treatments used to make cancer care impossible for many. Some cancer therapies can cost more than $15,000. Pet insurance now plays a big role in making those treatments more affordable.
North America recorded 7.03 million insured pets at the end of 2024 which represented a 12.2% increase from the 6.25 million documented in 2023 (NAPHIA, April 2025) . The U.S. insurance industry generated $4.7 billion in written premiums during 2024. Compared to the previous year this figure showed a 21.4% increase . The market is expected to reach $15.71 billion by 2030 according to expert predictions.
This growth affects oncology:
- More pet owners now support chemotherapy and targeted treatments, which maintains steady demand for pharmaceuticals.
- Veterinary clinics are putting money into diagnostic tools cold storage solutions, and strategies designed for cancer care.
- Insurance companies more often pay for biologics and allow participation in clinical trials.
- The typical age of pets entering coverage went down from 3.6 years in 2024 to 3.2 years in 2025 letting younger pets get insured before major illnesses arise (Spot Pet Insurance, December 2025).
Insurance hasn’t just removed financial hurdles. It has also boosted clinical standards across the board.
Why the Treatment Pipeline Is Growing in 2025–26
Years of focused effort and funding are shaping the new treatment environment. Major advances include:
In January 2025, IDEXX Cancer Dx was introduced. It’s a blood test that can find canine lymphoma up to six to eight months before symptoms show. Clinics can use it during routine checkups, with each test costing as little as $15. Right now, over 5,500 veterinary practices in the U.S. and Canada are offering it. By January 2026, IDEXX added the ability to detect mast cell tumors to the test. This update now helps identify over one-third of all canine cancer cases.
In March 2025, ELIAS Cancer Immunotherapy earned full USDA approval. It became the first approved autologous adoptive cell therapy to treat canine osteosarcoma. More than 100 treatment centers are already authorized to provide this therapy.
Gilvetmab, a specialized caninized monoclonal antibody that targets canine PD-1, has conditional USDA approval for treating melanomas and mast cell tumors. Full approval studies are still in progress.
Precision medicine is advancing . Tools like FidoCure analyze tumor genetic data to connect it with targeted treatments. By 2025, the AVMA registry included 57 active cancer studies focusing on dogs.
Big organizations are pouring in funding. Petco Love and Blue Buffalo expanded their partnership by investing $20 million into oncology programs at 12 U.S. veterinary schools. More treatments are hitting the market right now thanks to this growing pipeline.
The Supply Chain Opportunity: Why Distribution Matters
Clinical momentum triggers a growing need that often gets overlooked—dependable and compliant pharmaceutical distribution. As oncology moves out of academic institutions and into community practices and smaller clinics, the strain on the supply chain increases .
Pharmaceutical distributors in USA step in to address this critical demand. The process of delivering chemotherapy drugs and immunotherapy treatments and supportive care medications to veterinary clinics relies on cold-chain logistics and DSCSA 2025 traceability requirements and the use of established manufacturers as suppliers.
Key requirements for distributing veterinary oncology products:
- Maintaining cold-chain: Biologics and chemotherapy drugs need strict temperature control from production to clinic delivery.
- Meeting DSCSA 2025 rules: Federal law mandates complete serialization and trackability to manage specialty oncology medications .
- Ensuring trusted sourcing: Counterfeit and diverted oncology drugs pose a recognized risk in the U.S. market.
- Expanding access nationwide: Oncology care is no longer centered in big cities. Smaller towns and rural clinics must have access to the same products.
It’s rare to find list of pharmaceutical distributors partners with NABP accreditation expertise in specialty medicines, and logistics to cover the entire country. This rarity keeps driving heavy investment into the field.
A Look at 2026 in Practice
Veterinary oncology has developed into a complete veterinary discipline. The number of specialty clinics has started to increase in smaller urban areas. General veterinarians now possess better capabilities to handle cancer diagnosis discussions and they can easily refer patients to oncology experts.
The total count of board-certified veterinary oncologists in the United States reached 600 by the year 2024. The figure increased from 16 to its current total which represents an annual growth rate of 11.25 percent according to Today’s Veterinary Practice report from June 2025. Yet, the ACVIM job board showed over 100 open oncologist positions in early 2025. With 35 to 40 new diplomates joining , demand is surpassing supply.
Such trends are shaping the industry:
- Feline oncology is growing , with an expected annual growth rate of 12.38% until 2030. This growth comes from the increasing number of cats in about 40 million households in the U.S. (APPA, 2024).
- North America dominates the market with 53.9% of the global share, but the Asia-Pacific region is catching up fast and growing at over 10% each year.
- Funding for research is increasing . CureLab Veterinary has secured $15 million to develop its ElenaVet gene therapy platform. Spending in the U.S. pet industry is predicted to hit $157 billion by 2025.
Diagnostics are moving ahead of therapeutics — The veterinary oncology diagnostics market hit $3.15 billion in 2025. It is growing at an 8.7% annual rate through 2035. This growth is changing the focus in clinics from treating diseases after they appear to screening for them .
The systems, supply chains, finances, and clinical needs are all heading in the same direction. The era of companion animal oncology in 2026 is already here. Now, the big question is this: Which practices, manufacturers, and suppliers are prepared to keep up?
Your Reliable Choice for Veterinary Pharmaceutical Distribution
Drugzone Pharmaceuticals Inc., a wholesale pharmaceutical distributor licensed nationwide and accredited by NABP, is based out of New York. The organization provides healthcare services to humans and animals through its supply chain which meets DSCSA 2025 standards.
Drugzone operates a distribution center which covers an area of 20,000 square feet. The facility serves more than 8000 registered customers while maintaining an inventory of over 2000 pharmaceutical products which include generic drugs and specialized oncology treatments and biologics that require controlled temperature storage. The organization verifies each shipment according to FDA and NABP and DSCSA 2025 regulations.
As oncology for companion animals expands, Drugzone Animal Health is prepared to meet that demand. The company offers cold-chain shipping traceable deliveries across the country, and partnerships with top manufacturers in animal health.
FAQs
- Why is the field of companion animal oncology expanding more than other types of veterinary care?
Cancer rates in dogs and cats are quite high. Pet insurance has removed financial limits on care. By 2025 big steps happened with new regulations and advances in diagnostics. Clinical demand easier financial options, and better treatments are all coming together.
- What types of cancers are most often treated in pets?
In dogs, lymphoma makes up about a quarter of cases. Other common types are mast cell tumors, osteosarcoma, melanoma, and hemangiosarcoma. For cats , lymphoma and mammary tumors are most frequent. Dog cases still lead, but cat cancer cases are rising quickly.
- How does the vet oncology drug distribution work from others?
Cancer treatment drugs like chemotherapy agents, monoclonal antibodies, and biologics must be stored at low temperatures labeled , and traced to meet DSCSA requirements. A licensed distributor with NABP accreditation ensures products come from verified sources in proper condition.
